Clinical, biochemical and pathological features of initial and repeat transrectal ultrasonography prostate biopsy positive patients

International Journal of Urology

Volumn 11, Issue 4, 2004, Pages 225-231

  Yuen, John Shyi Peng ^a,b   Lau, Weber Kam Onn ^a   Ng, Lay Guat ^a   Tan, Puay Hoon ^b   Khin, Lay Wai ^a   Cheng, Christopher Wai Sam ^a  

^a MINISTRY OF HEALTH   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Biopsy; Methods; Prostate neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; DIGITAL RECTAL EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE TUMOR; TRANSRECTAL ULTRASONOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECTUM;

EID: 2342426317     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2003.00772.x     Document Type: Article

References (32)

1. Svetec D, McCabe K, Peretsman S et al. Prostate re-biopsy is a poor surrogate of treatment efficacy in localized prostate cancer. J. Urol. 1998; 159: 1606-8.
2. Daneshgari F, Taylor GD, Miller GJ, Crawford ED. Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies. Urology 1995; 45: 604-9.
3. Djavan B, Zlotta A, Remzi M et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J. Urol. 2000; 163: 1144-8.
4. Fowler JE Jr, Bigler SA, Miles D et al. Predictors of first repeat biopsy cancer detection with suspected local prostate cancer. J. Urol. 2000; 163: 813-18.
5. Djavan B, Remzi M, Schulman CC, Marberger M, Zlotta AR. Repeat prostate biopsy: Who, how and when? A review. Eur. Urol. 2002; 42: 93-103.
6. Djavan B, Ravery V, Zlotta A et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J. Urol. 2001; 166: 1679-83.
7. Catalona WJ, Beiser JA, Smith DS. Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J. Urol. 1997; 158: 2162-7.
8. Ellis WJ, Brawer MK. Repeat prostate needle biopsy: who needs it? J. Urol. 1995; 153: 1496-8.
9. Fleshner NE, O'Sullivan M, Fair WR. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol. 1997; 158: 505-8.
10. Perachino M, di Ciolo L, Barbetti V et al. Results of rebiopsy for suspected prostate cancer in symptomatic men with elevated PSA levels. Eur. Urol. 1997; 32: 155-9.
11. Ukimura O, Durrani O, Babaian RJ. Role of PSA and its indices in determining the need for repeat prostate biopsies. Urology 1997; 50: 66-72.
12. Keetch DW, McMurtry JM, Smith DS et al. Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostate biopsies. J. Urol. 1996; 156: 428-31.
13. Rietbergen JBW, Kruger AEB, Hoedemaeker RF et al. Repeat screening for prostate cancer after 1-year follow-up in 984 biopsied men: clinical and pathological features of detected cancer. J. Urol. 1998; 160: 2121-5.
14. Djavan B, Waldert M, Zlotta A et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of prospective European Prostate Cancer Detection Study. J. Urol. 2001; 166: 856-60.
15. Kurkan GC, Greene DR. Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? Br. J. Urol. 1999; 83: 34-8.
16. Karakiewicz PI, Bazinet M, Aprikian AG et al. Outcome of sextant biopsy according to gland Volume. Urology 1997; 49: 55-9.
17. Uzzo RG, Wei JT, Waldbaum RS, Perlmutter ASP, Byrne JC, Vaughan ED Jr. The influence of prostatic size on cancer detection. Urology 1995; 46: 831-6.
18. Eskew AL, Bare RL, McCullough DL. Systemic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J. Urol. 1997; 157: 199-202.
19. Levine MA, Ittman M, Melamed J, Lepor H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J. Urol. 1998; 159: 471-5.
20. Presti JC Jr, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J. Urol. 2000; 163: 163-7.
21. Vashi AR, Wojno KJ, Gillespie B, Oesterling JE. A model for the number of cores per prostate biopsy based on patient age and prostate gland. J. Urol. 1998; 159: 920-24.
22. Ng LG, Yip S, Tan PH, Yuen JSP, Lau W, Cheng C. Improved detection rate of prostate cancer using the 10-core biopsy strategy in Singapore. Asian J. Surg. 2002; 25: 238-43.
23. Tan HH, Gan E, Rekhraj I et al. Use of Prostate Specific Antigen (PSA) and Transrectal Ultrasound (TRUS) in the diagnosis of prostate cancer - A local experience. Ann. Acad. Med. Singapore 1995; 24: 550-56.
24. Borboroglu PG, Comer SW, Riffenburgh RH, Amling CL. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J. Urol. 2000; 163: 158-62.
25. Ito K, Ohi M, Yamamoto T et al. The diagnostic accuracy of the age-adjusted and prostate volume-adjusted biopsy method in males with prostate specific antigen levels of 4.1-10.0 ng/ml. Cancer 2002; 95: 2112-19.
26. Emiliozzi P, Longhi S, Scarpone P, Pansadoro A, DePaula F, Pansadoro V. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J. Urol. 2001; 166: 845-50.
27. Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 1998; 279: 1542-7.
28. Djavan B, Zlotta A, Waldert M et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5-4.0 ng/ml. Urology 1999; 54: 517-22.
29. Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 1991; 324: 1156-61.
30. Rommel FM, Agusta VE, Breslin JA et al. The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice. J. Urol. 1994; 151: 88-93.
31. Djavan B, Zlotta AR, Ekane S et al. Is onset of sextant biopsies enough to rule out prostate cancer? Influence of transition and total prostate Volumes on prostate cancer yield. Eur Urol. 2000; 38: 218-24.
32. Karakiewicz PI, Hanley JA, Bazinet M. Three-dimensional computer-assisted analysis of sector biopsy of the prostate. Urology 1998; 52: 208-12.